This review concentrates on the most common lipoprotein disorders. The rare congenital abnormalities of lipoprotein production, such as abetalipoproteinaemia are of interest mainly because they yield information about normal lipoprotein metabolism.
Cholesterol, triglycerides and phospholipids circulate as complexes with specific apoproteins, called lipoproteins. 'Free' fatty acids which are bound to albumin will not be discussed. Each of the lipoprotein classes contains all lipids in different proportions. Chylomicrons, which are not normally present in fasting plasma, and very low density lipoproteins (VLDL) carry most of the triglyceride. Lowdensity lipoproteins (LDL) transport most of the cholesterol. Lipoproteins are conventionally estimated in terms of their cholesterol content, since this lipid shows greatest variation between the lipoprotein classes. Phospholipids are not usually measured, because their concentration does not vary as much between lipoprotein classes and because methods for their analysis are tedious. Although kits are marketed for the estimation of total lipids, this analysis is obsolete for the purposes of clinical chemistry.
The justification for estimation of the individual lipoprotein classes stems from the results of epidemiological studies, which have suggested that increased concentrations of total and LDL-cholesterol are associated with an increased risk of development of coronary heart disease (CHD) and that a decreased highdensity lipoprotein (HDL)-cholesterol concentration is an independent risk-marker. [1] [2] [3] Opinions differ about any association between an increased triglyceride and risk for CHD. 4 Classification of the familial hyperlipoprotein-This paper was prepared at the invitation of the Working Party for Clinical Laboratory Investigation of the Association of Clinical Biochemists. aemias into five main types? provided much of the impetus for subsequent developments in our understanding of lipoprotein disorders. However, this classification was outlined before the importance of HDL-cholesterol as a riskmarker for CHD was appreciated and therefore does not take the concentration of HDL into account. Nevertheless, it is still widely used, since it is easier to say for example 'type V' rather than 'presence of chylomicrons and increase in VLDL'. In type V, although chylomicrons and VLDL are increased, HDL is often decreased and it is therefore more correct to use the term 'dyslipoproteinaemia' rather than 'hyperlipoproteinaemia' .
Apolipoprotein B (apoB) is the main protein in LDL and apolipoprotein A-I (apoA-I) that of HDL. The relative usefulness of assaying apoproteins and lipids to characterise lipoproteins has not yet been established. For example, a reduction in HDL-cholesterol level might either reflect a change in the amount of cholesterol in each HDL particle or a reduction in the number of normal HDL particles. In a study of subjects who showed subsequent clinical evidence of CHD,6 assay of apoA-I was considered to be a less accurate predictor than HDL-cholesterol. When survivors of myocardial infarction and control subjects were compared," apoA-I and apoB were found to be as effective discriminators for CHD as lipids in subjects less than 50 years old and to be better discriminators in older subjects.
The following tests are suitable for assessment of lipoproteins either on a routine basis or by arrangement with a reference laboratory: total cholesterol and triglyceride 'with visual inspection of samples; electrophoresis; HDLcholesterol (with total cholesterol used as an index of LDL-cholesterol); VLDL-, LDL-and HDL-cholesterol; apolipoproteins. Each of these categories will be considered in turn and recommendations will then be made about suitable assays for a laboratory in a District General Hospital (DGH) and for a reference laboratory. More specialised assays, such as qualitative and quantitative tests for isoproteins of apolipoproteins C and E, and assays of the enzymes of lipoprotein metabolism (e.g. lecithin-cholesterol acyl transferase) are outside the scope of this review.
Methods

SAMPLE
The patient should not have changed his diet during the previous 2 weeks. He should be questioned about possible alcohol abuse, because of the association between excess alcohol consumption and hypertriglyceridaemia. Blood lipids should not be analysed within 1 month of surgery or myocardial infarction. M Blood should be collected after an overnight fast (at least 12 h). The patient should, for example, always be in a sitting position for 10 minutes, since posture affects the concentration of all plasma proteins. At least two samples should be analysed before prescribing therapy.
. Either serum or plasma (preferably obtained by using a 2·5-4·0 rnrnol/l final concentration of disodium EDTA as anticoagulant) is usually suitable. The choice for a DGH laboratory will depend on convenience. A reference laboratory should use plasma or serum to which EDTA is added." Precautions should also be taken in the separation and storage of samples."
Lipoproteins are labile and serum or plasma should be analysed as soon as possible after sampling and stored at 4°C. We found that serum samples or isolated lipoprotein fractions could be stored at 4°C in the presence of EDTA for up to 5 days before electrophoresis or up to 8 days before estimation of cholesterol and triglyceride. III There was no advantage in adding mercurothiolate or p-chloro-mercuriphenyl sulphonate. However, it has recently been recommended that if samples are to be sent by post, three antimicrobial agents and EDTA should be added and they should be packed in ice.') When only total cholesterol and triglyceride are to be determined. samples can usually be stored at -20°C; although this is not suitable for all methods of assay. I I Concentrations of HDL-cholesterol are more stable at -2(J°C than at 4°C, when they can change appreciably. 12 Temperature fluctuations during storage can affect stability':' and samples stored at -65°C to -7(J°C may be more stable." Most samples in 16 ). An important advantage is that concentrated acids are not required. A reference laboratory should retain or have access to a chemical reference method.'? Enzymatic methods are based on the following reactions:
Cholesteryl ester +H20 (1) cholesterol esteras~cholesterol + fatty acid Cholesterol + O2 (2) cholesterol oxidase h i t 4 3 + H 0 --------. + > C 0 es --en--one 2 2 Cholestenone has a characteristic UV absorbance, but an extraction step is necessary to remove substances with similar absorbance. 1M Although this method has been suggested as suitable for a routine procedure, it is not satisfactory for a large workload. It has also been suggested as a reference method. 1M H 2 0 2 (reaction 2 above) can react with a chromogen in the presence of peroxidase or catalase. The reaction most commonly used in kits designed for automated analysis is:
Some kits include enzymes which remove endogenous pyruvate. The change in absorbance of NADH can be assessed either by end-point or kinetic procedures.
The comments already made about cholesterol standardisation apply also to triglyceride assays. Triolein, tripalmitate, tristearate and a defined mixture of these triglycerides have been advocated as primary standards. Unless the subject has been eating excessive amounts of glycerol-containing foods, such as non-dairy ice ESTIMATION OF PLASMA TOTAL TRIGLYCERIDE Fully enzymatic procedures have largely replaced chemical or fluorescent methods 22 . 2] for estimation of glycerol derived in vitro from circulating triglyceride by chemical or enzymatic means. The enzymatic reactions most commonly used in diagnostic kits can be summaried as:
Lipase/esterase Triglyceride • Glycerol + 3 fatty acids differences in reactivity between this and modified serum to which, for example, cholesterol in alcohol or detergent has been added (Ballantyne, Caine, unpublished). It is important not to accept the cholesterol concentration stated by the manufacturer. For example a commercial human serum preparation (lyophilised but otherwise unmodified), to which we have assigned a concentration of S·OO mmol/l and which gives a between-day coefficient of variation of less than 3'Yo is stated by the manufacturer to give values between 6·81 and 9·49 mmol/l based on twelve enzymatic procedures carried out using various analysers. Such rigid criteria need not be applied in selection of quality control material, but because of species differences in lipoprotein lipid concentrations I recommend the use of human-based material. 
The peroxidase reaction may give either falsely high or falsely low cholesterol values. IN Some commercial kits can be used for automated analysis on continuous-flow, discrete and centrifugal analysers. There is no significant interference from high bilirubin, haemoglobin or triglyceride levels. With the detergents used in modern kits, subtraction of a blank reading is unnecessary. If the appropriate enzymatic reagent is omitted, free and esterified cholesterol can both be estimated. However, for most purposes estimation of total cholesterol is sufficient.
Standardisation is one of the biggest problems in any cholesterol assay. 15 Organic solvents such as isopropanol cannot be used for preparing cholesterol standards for enzymatic procedures, but are used for chemical methods. Cholesterol standards dissolved in detergent such as sodium deoxycholate!" or in" alcoholdetergent mixtures, although satisfactory for manual procedures, do not have the same sampling characteristics as serum or plasma in automated equipment such as continuous-flow analysers. We and others/" have also found this to apply to commercial solubilised 'aqueous' standards and to some human-based quality assurance materials. Since cholesterol in human serum is mainly esterified, one could argue that the standard should also be in this form. I prefer to use human serum as a secondary standard and to calibrate this by a manual enzymatic procedure using unesterified cholesterol in detergent as primary standard and occasionally to assess this with a manual chemical reference method 17 using cholesterol in isopropanol as standard. These standardisation procedures and the validity of the assay conditions can be assessed with material from, for example, the Lipid Standardisation Laboratory, The Centre for Disease Control (CDC), Atlanta, Georgia, USA and the WHO Collaborating Centre, Institute for Clinical and Experimental Medicine, Prague, Czechoslovakia. The concentrations of standards from these sources 'will have been assigned by a reference method 17 or by isotope dilution/mass spectrometry." the proposed definitive method for cholesterol estimation. Our laboratory relies on pooled human serum from the Centre for Disease Control as reference material. Elevated cholesterol concentrations arc produced by adding lipoprotein concentrates prepared from human serum.
I advise the use of 'unspiked' human serum as a working standard, because we have found cream, the blank concentration in plasma is usually less than 0·1 mmoVI and can be ignored. However, commercial reference materials may contain significant amounts of free glycerol, either because it has been added to give an apparent increase in triglyceride or because breakdown of triglyceride has occurred during Iyophilisation and storage. The elevated triglyceride reference materials from the Centre for Disease Control, prepared by adding egg yolk extract to human serum pools, also have significant blank values.
PLASMA ELECTROPHORESIS
Electrophoresis of lipoproteins has been performed on a number of support media. Electrophoresis is a simple, and therefore useful, technique for the routine clinical biochemistry laboratory. The same system can be used as for conventional serum protein electrophoresis and no additional capital cost is incurred. Increased cholesterol with a normal triglyceride concentration is due to increased LDL, except in the rare hyper-a-lipoproteinaemia which will, be detected by estimation of HDL-cholesterol, and electrophoresis need only be performed if the triglyceride level is high or the cholesterol is low. However, marked chylomicronaemia may make interpretation of the lipoprotein pattern difficult. The chylomicrons may first be removed by leaving the sample to stand for 16 h at 4°C or by centrifugation.
In my opinion a commercially available thin film of agarose bonded to plastic is the most suitable medium for a clinical biochemistry laboratory.j" Solvent red 19/Cf and solvent black 3/Cf are the most popular stains, the choice being a matter of personal preference. These react with the ester bonds in the triglyceride molecule and cholesteryl esters but not with phospholipid and free cholesterol. Dye uptake therefore varies between lipoprotein classes. In obstructive jaundice, levels of free cholesterol and phospholipid may be markedly increased with the presence of an abnormal lipoprotein species (lipoprotein X). The electrophoretic pattern may be normal but the total cholesterol concentration increased. About 10% of normal subjects have significant amounts of Lp-a (or 'sinking pre-B') in their plasma, visible as an increased VLDL (pre-B) band on electrophoresis, but with a normal triglyceride concentration.
Qualitative assessment of electrophoretic patterns or their densitometric scans is usually adequate. Quantitation of the fractions is diffi-
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cult because of the problem described above and because the techniques of separation and staining need to be carefully controlled. A laboratory with a major interest in lipoproteins'f has recently reported encouraging results from a procedure involving electrophoretic separation of lipoproteins on agarose, precipitation of the lipoproteins on the gels with phosphotungstate-Mg2+ reagent, and measurement of the resulting turbidity by densitometry.
Electrophoresis on agarose is more sensitive for detection of chylomicronaernia.!" than visual inspection after standing (see above). Chylomicrons can be seen as a distinct halo of stained material surrounding the application well. If the triglyceride concentration is very high, triglyceride-rich particles (possibly chylomicrons or chylomicron remnants) may move towards the anode and this may obscure the usual LDL (~) and VLDL (pre-B) bands. In the presence of marked chylomicronaemia, VLDL may be prevented from entering the agarose."
ESTIMATION OF PLASMA
HDL-CHOLESTEROL
The recent evidence that a low plasma HDLcholesterol level is an independent risk-marker for CHD 2 • 3 is sufficiently convincing for me to recommend that all laboratories should estimate HDL-cholesterol as part of their routine lipid profile. Total cholesterol may be assumed to reflect LDL-cholesterol. The upsurge in clinical interest has led in turn to many investigations of techniques for measurement of HDL-cholesterol. The definitive procedure, which is based on ultracentrifugation, is not suitable for routine use. Simpler, less expensive procedures, which can be automated, have been devised in which the cholesterol concentration is estimated in the HDL-containing supernatant after precipitation of chylomicrons, VLDL and LDL.
The main differences between published methods lie in the precipitating agent. Most procedures use polyvalent anions/divalent cations, although procedures using polyethylene glycol 27 . 28 have been described. The most popular reagents in current use are heparin! Mn 2 + ,29. 30 dextran sulphate/Mg?" 31and phosphotungstate/Mg 2 + .32. 33 Although commercial kits are now available for all of these procedures, and may be convenient for laboratories with small workloads, I prefer to make up the simple reagents. The molecular basis of lipoprotein precipitation by polyanions/divalent cations has not been established, but may be due to interaction between negatively charged groups on the polyanions and positive groups on the protein moieties." Divalent metal ions react with negative groups such as phosphate moieties on the lipoproteins to facilitate formation of insoluble complexes.
In the United Kingdom in 1979 it was decided not to recommend only one procedure for routine use since it was considered that there was no proof that one method was better than the others" The controversy about methodology continues. Heparin/Mrr'" precipitation has been the most widely used procedure in population studies but Mn 2 + has been reported to interfere with some enzymatic assays for cholesterol. 35, 36 We find no such interference in the precipitation procedure of Warnick and Albers/" and analysis of HDL-cholesterol derived from plasma or ultracentrifugation fractions containing EDTA using the same manifold as used for total cholesterol and enzymatic reagents from Boehringer Limited (Lewes, UK) on an AutoAnalyser II (Technicon Ltd, Basingstoke, UK). The between-batch coefficient of variation (CV) is less than 5% and target values are obtained for specimens obtained from the Lipid Standardisation Laboratory, Center for Disease Control, Atlanta, (USA) suggesting that both precision and accuracy are acceptable. The group which established the heparin/Mrr'" procedure has recently advocated dextran sulphate/Mgt" precipitation as a 'proposed, selected method' Y The method is cheaper, and dextran sulphate is available in more consistent size ranges than is heparin. The same group found phosphotungstate/Mg/" to give variable results (although this would be disputed by others 32 • 33) , and rejected the use of polyethylene glycol because the HDL and other plasma proteins precipitate at concentrations only slightly higher than those needed to precipitate LDL. Other authors/" 28 have argued that precipitation with polyethylene glycol 6000 does give accurate HDL-cholesterol results. We will continue to use heparin/Mn!" until the controversy has been resolved, but I recommend any laboratory about to set up an HDL-cholesterol assay to consider the dextran sulphate/Mg/" procedure. It is claimed to yield a clearer supernatant from lipaemic serum than the heparin/Mrr'" technique.
The HDL-cholesterol should be estimated on the supernatant by the same enzymatic procedure used for total cholesterol. As previously discussed for estimation of total cholesterol, I recommend the use of human serum as secondary standard, provided that it is unmodified apart from Iyophilisation or is manipulated in such a way that its matrix properties are similar to those of patients' specimens. Commercial serum for HDL-cholesterol standardisation and quality control must be selected with care. Different commercial serum preparations show different within-and between-assay precisions and these may not agree with those on fresh, human plasma. 13. 37 Their properties are affected by the method of precipitation 13. 37 and may also depend on the method of estimation of cholesterol. The precision may also vary from batch to batch of a manufacturer's material. For example Precilip (Boehringer Ltd) was found by one group to give a coefficient of variation (CV) of 17% when analysed at about weekly intervals for 20 weeks.P whereas in our laboratory the CV within successive 20 week periods during the last 2 years has been consistently less than 5%.
ESTIMATION OF PLASMA VLDL-, LDL-AND
HDL-CHOLESTEROL VLDL-and LDL-cholesterol levels may be roughly calculated from the total cholesterol and triglyceride and HDL-cholesterol concentrations, unless there is chylomicronaemia, the triglyceride concentration is more than 4·5 mmol/l, or the subject has the relatively rare type III hyperlipoproteinaemia. 38. 39 The reference procedure for quantitation of lipoproteins is preparative ultracentrifugation at density 1·006 kg/I (plasma protein-free density) to separate VLDL with or without chylomicrons ('top' fraction) from LDL, HDL and other plasma proteins ('bottom' fractionj.t" 41 After precipitation of LDL from the 'bottom' fraction as described above, HDL-cholesterol is estimated in the same batch as total plasma, 'top' and 'bottom' fractions. LDL-cholesterol is obtained by difference. This procedure should be available in a reference laboratory, but is too expensive for general use.
Simpler procedures have been described, but are not generally accepted. These include sequential precipitation with polyanions/divalent cations, agarose column chromatography and ultrafiltration. Electrophoresis followed by quantitative densitometry is feasible.f' but regular cross-checks with ultracentrifugation must be made to ensure that correction factors for differential dye uptake have not changed. In a preliminary report'f size-exclusion highperformance liquid chromatography (HPLC) was used to separate plasma lipoproteins. This application deserves further evaluation, because of the increasing use of HPLC equipment in clinical chemistry laboratories. At present I recommend that a DGH laboratory should assess VLDL ± chylomicrons and LDL by qualitative electrophoresis and by approximate calculatiorr'": 3' 1 from total triglyceride and total-and HDL-cholesterol. If accurate quantitation is needed, samples should be referred to a reference laboratory for ultracentrifugation.
ESTIMATION OF PLASMA APOLIPOPROTEINS
Immunological methods have been most often used to estimate apoA, and apoB. Radial immunodiffusiont'': 44 and electroimmuno-assay44-46 are suitable only for small workloads. Electroimmunoassay has the advantage that apoA, and apoB can be estimated sirnultaneously.?" Radioirnmunoassay'I'<" and immunonephelornetry'": 41<-52 are more satisfactory for larger workloads. Since both apoA, and apoB are present in plasma at relatively high concentration (mean normal adult concentration about 1·3 and 1·0 gil respectively), the greater sensitivity possible with radioimmunoassay is not essential. Immunonephelometry has the advantages that it does not require the use of isotopes, can be performed manually more quickly than radioimmunoassay and is more readily automated. It has been fully investigated and is probably the method of choice for routine analyses. ApoA I is found mainly in plasma HDL; in samples with very high triglyceride concentrations the high background turbidity may be reduced by precipitation or extraction procedures'S before apoA, is estimated. This method cannot be used during estimation of apoB, which is present in significant amounts in the plasma VLDL and chylomicrons, which cause the turbidity. Addition of lipolytic enzyrnes'" or detergent" may be employed to decrease the size of these lipoprotein particles.
Although kits are available for estimation of these apolipoproteins, I am not convinced that a DGH laboratory should perform these assays. Not only is there no consensus on standardisation and quality assurance, but also the relative value of apolipoproteins and lipoprotein-lipids in the assessment of dyslipoproteinaemias has not been fully resolved. Assays for apoA, and apoB should be performed by a reference laboratory, using immunonephelometry. Such a laboratory should also estimate the apolipopro-teins C (apoC), particularly apoC-II, 5:>--55 the coenzyme of lipoprotein lipase, a deficiency of which has been described in some subjects with hypertriglyceridaemia. An apolipoprotein E (apoE) assay should also be maintained for characterisation of type III hyper-Iipoproteinaemia. Total apoE is high, usually with phenotype E2/2, although some individuals have phenotype E4/2. 56. 57 
Discussion
The results of recent epidemiological and metabolic studies have increased our appreciation that increased LDL and decreased HDL concentrations are risk-markers for coronary heart disease.v'': 5M, 5' 1 The clinical chemist should respond to this development by maintaining a knowledge of the inter-relationships in lipoprotein metabolism58, 60 and therefore of the most appropriate tests for the assessment of plasma lipoproteins. He must also be able to advise on the disorders associated with secondary dyslipoproteinaemias and their investigation.
Each laboratory should determine its own reference ranges. Ours, based on studies of about 80 apparently normal subjects, are similar to those determined on a population sample elsewhere in the United Kingdorn.?' However, since lipoproteins are influenced by diet, the reference range may not be the same as the desirable range. It is, for example, very difficult to decide the optimum mean cholesterol concentration. It has been suggested that it may be about 4·8 mrnol/l"! or somewhat higher.P' Patterns of abnormalities based on determination of total cholesterol and triglyceride and standing the plasma overnight at 4°C have recently been clearly summarised."! Some of the primary dyslipoproteinaemias are rare, e.g. abetalipoproteinaemia, and are of interest mainly for the light which they throw on normal lipoprotein metabolism. The 'classical' cause of an increased cholesterol is familial hypercholesterolaemia. This is an autosomal dominant condition in which there is defective receptor-mediated uptake of LDL-cholesterol. Although the homozygous form is rare, the heterozygous form is a likely diagnosis in a subject with a markedly raised plasma cholesterol, tendinous xanthomata and a strong family history of atherosclerosis. However, most subjects do not have one of the welldefined monogenic lipoprotein disorders. Hyperlipidaemia may then depend on an interaction between genetic and environmental factors. For example, a subject with a genetic predisposition to elevated LDL levels may be unusually sensitive to the effect of dietary cholesterol.
The interaction of hypertriglyceridaemia and alcohol consumption is another example of this phenomenon. Dyslipoproteinaemia will not then consistently occur in the individual and may also manifest in different ways throughout his family.
On which subjects should one assess lipoproteins? This partly depends on the philosophy of the laboratory-whether a profile of tests is performed on all samples or whether a selective approach is adopted. In the latter case, lipoproteins should be assessed on subjects with evidence of coronary heart disease (CHD) or a strong family history of the disease, and on subjects with xanthomata. They are sometimes included in screening programmes, associated with insurance or occupational health surveys. If hypercholesterolaemia is clear-cut and secondary causes have been excluded, then family studies should be performed. Although there is debate about the value of lipid-lowering therapy for survivors of myocardial infarction,62 these subjects should certainly be screened to identify propositi for familial hypercholesterolaemia. Blood should not be taken until at least 1 month after infarction to avoid the confounding effects of the metabolic response to trauma." Younger relatives can then be identified and given therapy before atherosclerosis has become life threatening. It is not essential to identify relatives of cases who have hypertriglyceridaemia only, since an association between this finding and CHD is not clearly established."
The most useful tool for assessing lipoproteins remains accurate and precise assessment of plasma total cholesterol and triglyceride.j" The tests which I recommend for both DOH and reference laboratories are summarised in Table  1 . A DOH laboratory should estimate total cholesterol and triglyceride and assess the appearance of the plasma after standing for 16-24 h. It should also estimate HDLcholesterol on all samples requesting 'Lipids' because of the convincing evidence that HDL may be an independent risk-marker. 1-3 In most cases VLDL and LDL can then be approximately calculated'": 39 Lipoprotein X is rarely used as a marker of obstructive jaundice in this country, because it correlates with alkaline phosphatase and conjugated bilirubin levels, and does not clearly differentiate between extra-hepatic and intrahepatic obstruction.P' Many mild lipoprotein disorders, particularly when secondary to other disease, can be adequately assessed and the underlying cause treated without full characterisation of lipoproteins. If a marked abnormality is found (with the probable exception of an increased triglyceride concentration due to excessive alcohol consumption), a sample should be sent to a reference laboratory for specialised procedures including ultracentrifugation. The laboratory should also be able to assess the response to therapy. Although there are dietary and drug therapies for the primary dyslipoproteinaemias, most clinicians now use drugs less frequently. 64. 65 The need for serial estimations on patients is one of the reasons why careful quality control is important. A reference laboratory should maintain betweenday coefficients of variation of less than 3% for total cholesterol and triglyceride and less than 5% for HDL-cholesterol.
In the future it is likely that estimation of apolipoproteins apoA, and apoB will be more widely applied. This assumes that agreement will be reached on methods of analysis and on standardisation procedures.P": 67 It also assumes that further clinical studies will support the value of these estimations; for example, does an increased apoB and a decreased apoA constitute a 'risk-profile' even when the total cholesterol concentration is normal'F! It may be that further developments in the characterisation of lipoprotein subfractions will produce clinically useful information. There is evidence that HDL z is the subfraction which confers the putative protective effect of an increased HDLcholesterol. Women, who are less prone to CHD, have higher HDL z concentrations than men,6Il while male survivors of myocardial infarction have lower HDL z concentrations than apparently normal men. 6 Y Reference laboratories are attempting to develop simpler methods for assessment of subfractions of, for example, HDL. 7lJ
There have been tremendous advances in recent decades in our understanding of disorders of lipoprotein metabolism and their relationship to the development of CHD. This area promises to remain fruitful for clinical chemists, who have the opportunity to participate in technological developments and to collaborate in clinical studies with members of other disciplines.
